2. Academic Validation
  3. Preclinical and clinical development of deferitrin, a novel, orally available iron chelator

Preclinical and clinical development of deferitrin, a novel, orally available iron chelator

  • Ann N Y Acad Sci. 2005;1054:492-4. doi: 10.1196/annals.1345.071.
Joanne M Donovan 1,  Melissa Plone,  Rafif Dagher,  Mark Bree,  Judith Marquis
Affiliations

Affiliation

  • 1 Genzyme, Drug Discovery and Development, 153 Second Ave., Waltham, MA 02492, USA. joanne.donovanmd@genzyme.com
PMID: 16339704 DOI: 10.1196/annals.1345.071
Abstract

Deferitrin, a novel, orally available iron chelator, is in the early stage of clinical development for the treatment of chronic iron overload due to transfusional therapy. Preclinical pharmacology studies demonstrate iron excretion largely by the fecal route. Initial clinical studies have shown deferitrin to be well absorbed. Further clinical studies are ongoing to determine the efficiency and safety of deferitrin.

Figures
Products